AAVantgarde Reports Gene Therapy Trial Data at EURetina 2026
AAVantgarde shared updated Phase 1/2 results for Usher syndrome and preclinical findings for Stargardt disease at a major European retinal conference.
Gene therapy biotech AAVantgarde presented new clinical and preclinical data at EURetina 2026, highlighting progress across two rare inherited eye disease programs targeting significant unmet medical needs.
The company shared updated findings from its LUCE-1 Phase 1/2 study evaluating AAVB-081 in patients with Usher syndrome type 1B, a severe genetic condition that causes combined hearing loss and progressive vision deterioration. The LUCE-1 data represent the company's most advanced clinical program and offer an early look at how the gene therapy candidate is performing in human subjects.
Read more The General Insurance Teams Up With Street Fighter for Car Giveaway →
AAVantgarde also presented preclinical data backing the clinical translation of AAVB-039, a separate candidate aimed at treating Stargardt disease, the most common inherited form of macular degeneration in young patients. The preclinical package is intended to support a regulatory pathway toward human trials for that program.
The dual presentation at EURetina 2026 underscores the company's broader strategy of advancing an ocular gene therapy pipeline across multiple inherited retinal dystrophies simultaneously. Both conditions currently lack approved disease-modifying treatments, making gene therapy an area of considerable scientific and commercial interest. Analysts tracking the rare disease space have noted that inherited retinal disorders represent a proving ground for next-generation viral vector delivery platforms.
Continue reading at GlobeNewswire - Industry News on Financial Services.
